

Supporting data

Isolation, crystal structure and *in silico* aromatase inhibition activity of ergosta-5,22-dien-3 β -ol from the fungus *Gyromitra esculenta*

Yerlan Melsuly Suleimen^{1,2*}, Ahmed M. Metwaly^{3*}, Ahmad E. Mostafa³, Eslam B. Elkaeed⁴, Hong-wei Liu⁵, Buddha Bahadur Basnet⁶,
Raigul Nurbekkyzy Suleimen⁷,
Koblandy Muboryakovich Turdybekov⁸, Kristof Van Hecke⁹

¹ Sh. Ualikhanov Kokshetau University, Kokshetau, Kazakhstan

² Republican collection of microorganisms, Nur-Sultan, Republic of Kazakhstan

³ Pharmacognosy and Medicinal Plants Department, Faculty of Pharmacy, Al-Azhar University, Cairo, Egypt.

⁴ Department of Pharmaceutical Sciences, College of Pharmacy, AlMaarefa University, Ad Diriyah 13713, Riyadh, Saudi Arabia.

⁵ State Key Laboratory of Mycology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, 100101, China

⁶ Faculty of Sciences, Nepal Academy of Science and Technology, Khumaltar, Lalitpur, Nepal

⁷ L.N. Gumilyov Eurasian National University, Nur-Sultan, Kazakhstan

⁸ Department of Physics of Academician E.A. Buketov Karaganda University, Karaganda, 100028, Kazakhstan

⁹ XStruct, Department of Chemistry, Ghent University, Ghent, B-9000, Belgium

* Correspondence should be addressed to;

Yerlan Suleimen: syerlan75@yandex.kz; Tel.: +7-701-683-4983 Orcid: <https://orcid.org/0000-0002-5959-4013>

Ahmed M. Metwaly: ametwaly@azhar.edu.eg Orcid: <https://orcid.org/0000-0001-8566-1980>

Table of Contents		Page
S.1. Materials and Methods		3
Figure S1: ^1H -NMR (500 MHz, CDCl_3) Spectrum of 1		6
Figure S2: ^{13}C -NMR (125 MHz, CDCl_3) Spectrum of 1		7
Figure S3: DEPT (125 MHz, CDCl_3) Spectrum of 1		8
Figure S4: ^1H - ^1H Cosy (500 MHz, CDCl_3) Spectrum of 1		9
Figure S5: HMQC Spectrum of 1		10
Figure S6: HMBC Spectrum of 1		11

S.1. Experimental

S.1.1. Isolation of **1**

The raw material of *G. esculenta* was collected in summer in the vicinity of the city of Karkaraly, Karaganda region, Kazakhstan. *G. a esculenta* was extracted *via* adding 300 mL of MeOH to 207.5 g of a semi-dried powder and sonicated at 40–50 °C for 3 hrs. The procedure was repeated 3 times per day. The obtained extracts were combined and evaporated under reduced pressure. Total weight of the obtained extract – 62.9 g.

The total extract was subjected to SiO₂ column (400 g) using hexane – EtOAc and CH₂Cl₂ – MeOH as mobile phases in a manner of increasing polarity. Pure white colored crystal of **1** was obtained from fraction 54 (hexane – EtOAc 1: 10).

S.1.2. X-ray analysis

X-ray intensity data for the compound C₂₈H₄₆O · H₂O were collected at 100 K, on a Rigaku Oxford Diffraction Supernova Dual Source (Cu at zero) diffractometer equipped with an Atlas CCD detector using ω scans and CuK α ($\lambda = 1.54184 \text{ \AA}$) radiation. The images were interpreted and integrated with the program CrysAlisPro⁶². Using Olex2⁶³, the structure was solved by direct methods using the ShelXT structure solution program and refined by full-matrix least-squares on F² using the ShelXL program package^{64, 65}. Non-hydrogen atoms were anisotropically refined and the hydrogen atoms in the riding mode with isotropic temperature factors fixed at 1.2 times U(eq) of the parent atoms (1.5 times for methyl and hydroxyl groups). The absolute configuration was established showing a refined Flack parameter of 0.0(2).

CCDC 2060747 contains the supplementary crystallographic data for this paper. These data can be obtained free of charge from The Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk/structures.

Details of the X-ray crystal structure data collection and refinement are given in Table 7.

Table 7. Crystal data and details of the data collection and structure refinement for hydrate brassicasterol.

Parameters	hydrate brassicasterol
Empirical formula	C ₂₈ H ₄₆ O · H ₂ O
Formula weight (g/mol)	416.66
Temperature (K)	100(1)
Crystal system	monoclinic
Space group	<i>P</i> 2 ₁
<i>a</i> (Å)	9.8621(2)

<i>b</i> (Å)	7.5289(2)
<i>c</i> (Å)	34.4423(5)
θ (°)	93.926(1)
Volume (Å ³)	2551.37(9)
<i>Z</i>	4
ρ_{calc} (g/cm ³)	1.085
μ (mm ⁻¹)	0.495
<i>F</i> (000)	928.0
Crystal size (mm ³)	0.351 × 0.129 × 0.072
Radiation	CuK α (λ = 1.54184)
2 θ range for data collection (°)	7.718 to 150.484
<i>T</i> _{min} , <i>T</i> _{max}	0.760, 1.000
Index ranges	-12 ≤ <i>h</i> ≤ 12, -8 ≤ <i>k</i> ≤ 9, -40 ≤ <i>l</i> ≤ 43
Reflections collected	47210
Independent reflections	9920 [<i>R</i> _{int} = 0.0542, <i>R</i> _{sigma} = 0.0442]
Data/restraints/parameters	9920/1/561
Goodness-of-fit on <i>F</i> ²	1.037
Final <i>R</i> indexes [<i>I</i> ≥ 2 σ (<i>I</i>)]	<i>R</i> ₁ = 0.0738, <i>wR</i> ₂ = 0.1944
Final <i>R</i> indexes [all data]	<i>R</i> ₁ = 0.0773, <i>wR</i> ₂ = 0.1994
Largest diff. peak/hole (e·Å ⁻³)	0.54/-0.34
Flack parameter	0.0(2)

S.1.3. Molecular Docking studies

Crystal structure of aromatase [PDB ID: 3S7S, resolution: 3.21 Å] was obtained from Protein Data Bank. The docking investigation was accomplished using MOE2014 software. At first, the crystal structure of aromatase was prepared by removing water molecules. Only one chain was retained besides the co-crystallized ligand (EXM). Then, the selected chain was protonated and subjected to a minimization of the energy process. Next, the active site of the target protein was defined.

Structures of ergosta-5,22-dien-3 β -oloid EXM were drawn using ChemBioDraw Ultra 14.0 and saved in MDL-SD format. Such a file was opened using MOE to display the 3D structures which were protonated and subjected to energy minimization. Formerly, flexible alignment was performed using the alignment protocol of MOE. Then, validation of the docking process was performed by docking the

co-crystallized ligand against the isolated pocket of the active site. The produced RMSD value indicated the validity of the process. Finally, docking of the tested compounds was done through the dock option inserted in compute window. For each docked molecule, 30 docked poses were produced using ASE for scoring function and force field for refinement. The results of the docking process were then visualized using Discovery Studio 4.0 software⁶⁶⁻⁷².


S.1.4. *In silico* ADMET studies

ADMET descriptors (absorption, distribution, metabolism, excretion and toxicity) of ergosta-5,22-dien-3 β -ol and the co-crystallized ligand were determined using Discovery studio 4.0. At first, the CHARMM force field was applied then the compounds were prepared and minimized according to the preparation of small molecule protocol. Then ADMET descriptors protocol was applied to carry out these studies^{66, 67}.

S.1.5. *In silico* Toxicity studies


The toxicity parameters of ergosta-5,22-dien-3 β -ol and the Co-crystallized ligand were calculated using Discovery studio 4.0. At first, the CHARMM force field was applied then the compounds were prepared and minimized according to the preparation of small molecule protocol. Then different parameters were calculated from the toxicity prediction (extensible) protocol.

S#393093
single_pulse





Figur S1. ¹H spectrum of compound 1

S#380071
single pulse decoupled gated NOE




Figur S2. ^{13}C spectrum of compound 1





Figur S4. cosy spectrum of compound 1



Figur S5. HMQC spectrum of compound 1

